



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>C07H 21/00, C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/00868</b>  <b>(43) International Publication Date:</b> 24 January 1991 (24.01.91)
<b>(21) International Application Number:</b> PCT/GB90/01040 <b>(22) International Filing Date:</b> 5 July 1990 (05.07.90)  <b>(30) Priority data:</b> 8915607.9      7 July 1989 (07.07.89)      GB 8921327.6      21 September 1989 (21.09.89)      GB 9008274.4      11 April 1990 (11.04.90)      GB  <b>(71) Applicant (for all designated States except US):</b> NATIONAL RESEARCH DEVELOPMENT CORPORATION [GB/GB]; 101 Newington Causeway, London SE1 6BU (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> DAY, Philip, John, Royle [GB/GB]; Blagdon Road, Haden Coppice, Halesowen, West Midlands B63 3PX (GB). FOX, John, Edward [GB/GB]; 34 Old Ham Lane, Pedmore, Stourbridge, West Midlands DY9 0UN (GB). WALKER, Matthew, Robert [GB/GB]; 51 Frederick Road, Selly Oak, Birmingham B29 6NX (GB).		<b>(74) Agent:</b> PERCY, Richard, Keith; National Research Development Corporation, Patent Department, 101 Newington Causeway, London SE1 6BU (GB).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> IMMOBILISED POLYNUCLEOTIDES  <b>(57) Abstract</b>  <p>Nucleotides can be linked from a 5'-phosphate residue to a support via a dithio (-S-S-) linkage. Polynucleotides thus immobilised can be used in the polymerase chain reaction (PCR) at which a temperature of 90°C is typically required. The -S-S- linkage can be produced by reaction of a thiolated support with a 5'-(thiol-terminated) polynucleotide. For ease of hybridisation of the immobilised polynucleotide, the sequence to be hybridised should be adequately spaced from the support. The invention is useful in any situation in which a polynucleotide such as DNA is required to be separated as a solid phase from a liquid phase, especially in heterogeneous assays and to isolate products of the PCR.</p>		

# DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CC	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TC	Togo
				US	United States of America

- 1 -

IMMOBILISED POLYNUCLEOTIDESBackground to the invention1. Field of the invention

This invention is in the field of assays for polynucleotides, principally DNA, and relates to the immobilisation of polynucleotides on a support material.

05 2. Description of the prior art

The polymerase chain reaction (PCR), see U.S. Patent 4,683,202 (Mullis), R.K. Saiki *et al.*, Science 230, 130-154 (1985) and H.A. Erlich *et al.*, Nature 331, 461-462 (1988), allows a nucleic acid sequence to be amplified. As applied to DNA, the process comprises the steps of denaturing a duplex to produce two single-stranded (ss) molecules, synthesising complementary DNA to each ss DNA by oligonucleotide priming synthesis, thereby producing a duplex from each ss DNA molecule, denaturing the duplex to produce two ss DNA molecules (one of the original length, one of length governed by the position at which priming began), using each of these molecules as the template for a further primed synthesis and so on for as many cycles as desired. In view of the use of heat to denature the DNA, the DNA polymerase enzyme used for the primed synthesis is preferably one which is stable at the denaturing temperature, in order to avoid addition of fresh polymerase at each cycle. The use of a heat-stable polymerase from Thermus aquaticus enables the PCR amplification of DNA (directly from DNA, or indirectly from RNA) to be carried out at temperatures ranging from 30 to 100°C, at various stages of the process and dependent on the nature of the sequence to be amplified, in automated equipment.

The PCR is potentially of immense value in diagnostics since it enables either the analyte nucleic acid or the duplex produced upon hybridisation of the analyte to a labelled probe to be amplified and thereby very small amounts of nucleic acid to be detected. An amplification of  $10^{20}$  within 4-6 hours is possible.

- 2 -

Hybridisation of native and/or synthetic DNA to complementary DNA/RNA sequences is critical to the performance of PCR and many other DNA/RNA assays. Detection of analyte sequences with or without amplification is also dependent on hybridisation of complementary sequences to a labelled probe. Most of these present techniques require immobilisation of the analyte or probe sequences (e.g. to nylon membranes) prior to hybridisation. Consequently the time and complexity of the protocols increases whilst non-specific linkage employed reduces the amount of specific analyte or probe available for hybridisation. Separation and concentration of amplified analyte sequences by solution hybridisation following PCR is highly desirable to readily enable detection and increase sensitivity (and quantitation) and decrease incubation times by favouring the kinetics.

The linkage of oligonucleotides to solid phase particles for collection, separation and detection of analyte sequences by solution hybridisation has been investigated by several groups [see review by J.A. Matthews and L.J. Kricka, *Anal. Biochem.* **169**, 1-25 (1988)]. Matrices commonly used have been control pore glass [S.S. Ghosh and G.F. Musso, *Nucleic Acid Res.* **15**, 5353-5390 (1987)], latex [S.F. Wolf *et al.*, *Nucleic Acid Res.* **15**, 2911-2926 (1987)], polystyrene [Y. Nagata *et al.*, *FEBS Lett.* **183**, 379-382 (1985)], cellulose [T. Goldkorn and D.J. Prockop, *Nucleic Acids Res.* **14**, 9171-9191 (1986)] and magnetically attractable beads of cellulose [J.A. Langdale and A.D.B. Malcolm, *Biochem. Soc. Trans.* **12**, 693-694 (1984) and P.J. Nicholls, J.A. Langdale and A.D.B. Malcolm, *Biochem. Soc. Trans.* **15**, 140 (1987)] or styrene polymer [V. Lund *et al.*, *Nucleic Acids Res.* **16**, 10861-10880 (1988)]. Several chemistries have been applied to the attachment of the oligonucleotides, based on linkage via carboxy or amino groups (e.g. using carbodiimide or cyanogen bromide or tosyl-activated beads) [J.A. Langdale and A.D.B. Malcolm, *Biochem. Soc. Trans.* **12**, 693-694 (1984), R. Polsky-Cynkin *et al.*, *Clin. Chem.* **31**, 1438-1443 (1985), J.A. Langdale and A.D.B. Malcolm, *Gene* **38**,

- 3 -

201-210 (1985), V. Lund *et al.*, Nucleic Acids Res. 16, 10861-10880 (1988), P.J. Nicholls, J.A. Langdale and A.D.B. Malcolm, Biochem. Soc. Trans. 15, 140 (1987), L. Clerici *et al.*, Nucleic Acid Res. 6, 247-257 (1979), D. Rickwood Biochem. Biophys. Acta 240, 515-521 (1973), H. Bunemann, P. Westhof and R.G. Herrmann, Nucleic Acid Res. 10, 7163-7181 (1982) and A. Jungell-Nortamo *et al.*, Molecular and Cellular Probes 2, 281-288 (1988)] or introduction of electrophilic groups at the 5' end of the oligo and then reacting the oligo with a nucleophilic residue on the support [J.N. Kremsky *et al.*, Nucleic Acid Res. 15, 2891-2909 (1987)]. Specific attachment of oligonucleotides has been achieved to varying degrees by all methods (generally of 10-20 µg or 0.04-1.0 nM oligonucleotide per mg of beads). However, the availability of amino and carboxyl groups on the nucleotide side arms resulted in poor specific coupling via the 5' end of the oligonucleotide. Consequently, only a small proportion of the attached oligonucleotide is available for hybridisation (typically femtomole amounts of analyte per mg of beads) [S.S. Ghosh and G.F. Musso, Nucleic Acid Res. 15, 5353-5390 (1987)].

In the Goldkorn and Prockop paper, oligo-dT cellulose is linked to an oligonucleotide via a polynucleotide chain by the steps of (1) poly dA-tailing the 3'-ends of a double-stranded oligo, (2) hybridising the poly dA-tailed DNA to the oligo-dT cellulose, (3) filling in the gap between the last dT of the oligo-dT cellulose and the 5'-end nucleotide complementary to the 3'-nucleotide onto which the poly A tail was added, by the T4 ligase/Klenow fragment method and (4) separating by heat denaturation the filled-in strand, now attached to the oligo dT cellulose, from the other strand, which is attached to the oligo-dT cellulose only indirectly, via its complementary strand, as a result of the dA-dT hybridisation. This procedure involves multiple steps and expensive reagents and is exclusive to cellulose, this being the only known support to which a dT chain can readily be linked.

- 4 -

Various other esoteric linkages are mentioned in the Matthews and Kricka review paper, see Table 7 on page 15.

05 A-C. Syvänen, Nucleic Acids Research 16, 11327-11338 (1988) describe 5'-biotinylating DNA molecules and joining them to avidin-coated polystyrene particles. The particles are used to capture 5'-biotinylated products of the PCR. This methodology cannot be used in the PCR itself because the biotin/avidin interaction is not sufficiently heat-stable.

10 Summary of the invention

It has now been found that nucleotides can be linked to a support via a dithio (-S-S-) linkage, which results in exceptional stability of linkage. In particular, the supported polynucleotide can participate in a PCR reaction carried out at  
15 elevated temperature. The dithio linkage is formed by coupling a thiol (-SH) group or a reactive derivative thereof on the polynucleotide with a thiol group or reactive derivative thereof on the support. Further, when a polynucleotide is thus linked, then, provided that the support is sufficiently distanced from  
20 the sequence of interest, that sequence can be hybridised strongly to a labelled complementary probe.

Since the dithio linkage is stable at the highest temperature (about 90°C) typically used in the polymerase chain reaction (PCR), polynucleotides thus linked to beads can be used in the  
25 PCR. They are also useful for a variety of purposes in heterogeneous assays of nucleic acids.

Accordingly, an important feature of the invention consists in an immobilised polynucleotide material comprising a support bound to a 5'-end of at least one polynucleotide through a  
30 linkage which includes a dithio (-S-S-) group. The term "polynucleotide" encompasses DNA, RNA, oligonucleotides and any modified or labelled form of conventional nucleic acid in which pairable bases are arranged in helical chains.

An important subsidiary feature comprises an immobilised  
35 polynucleotide material comprising a support bound to a 5'-end of

- 5 -

at least one polynucleotide which contains a "c-target" base sequence complementary to a "target" base sequence of interest, said support being bound through a linkage as defined above and which is effective to distance or space the support from the "c-target" sequence so as to permit the c-target sequence to hybridise to the target sequence. (References herein to hybridisation are to be construed to include annealing of primers to longer sequences as occurs in the PCR).

It has been found that the linkage in this invention results in a particularly high degree of hybridisation, probably because, unlike the CNBr and carbodiimide methods of attachment normally used, it is specific to 5'-end attachment. It is believed that in these conventional methods, there is some reaction between amino groups on DNA bases and the activated supports. The resultant attachment of supports to mid-chain bases would interfere with base-pairing and therefore hybridisation.

The invention further provides a method of carrying out a polymerase chain reaction (PCR) in which an immobilised polynucleotide material of the invention is substituted for either or both of the oligonucleotide primers used in the PCR and the amplified product of the PCR is separated on the solid phase. Thus, as applied to a conventional PCR, the c-target sequences of two immobilised polynucleotides anneal to respective target sequences of the polynucleotide to be amplified, one target sequence being at a 5'-end of one strand and the other being at the 5'-end of the other strand.

In another aspect, the invention includes a method of heterogeneous assay for an analyte nucleic acid, which comprises subjecting the immobilised polynucleotide material of the invention, having a c-target sequence, to hybridisation with the target sequence of analyte nucleic acid present in a liquid phase analyte, separating the phases and determining the occurrence or extent of hybridisation. Preferably, the analyte nucleic acid is labelled either directly or by hybridisation at a second site thereof with a labelled complementary polynucleotide. Such an

- 6 -


assay is preferably used in conjunction with a liquid phase PCR, to detect a product of the PCR. It can also be used in any nucleic acid assay context.

The invention further includes a method of producing an  
 05 immobilised polynucleotide material of the invention which  
 comprises reacting a 5'-(thiol-terminated) derivative of a  
 polynucleotide with a support having a thiol group thereon,  
 either or both of said thiol groups being optionally derivatised  
 as co-reactive -S-S- linkage-producing derivatives, to form a  
 10 said -S-S- linkage between said thiol groups. Any chain atoms  
 (a) between support and its pendant thiol group and (b) between  
 5'- nucleotide phosphate residue and its pendant thiol group are  
 preferably thermally stable at the maximum temperature likely to  
 be essential in the PCR reaction, normally 90°C-100°C.

15 For most, but not necessarily all, uses of the invention, the  
 support needs to be distanced from the sequences which it is  
 desired to hybridise. Desirably, the spacing is provided wholly  
 by the linkage, that is to say between the 5'-end of the last  
 nucleotide and the support. However, it could be provided partly  
 20 or wholly by attaching a sequence of irrelevant nucleotides to  
 the last nucleotide of interest and providing the thiol  
 termination on the last of the irrelevant nucleotides. In other  
 words, the spacing between the last nucleotide of interest,  
 usually a c-target nucleotide, and the support can contain  
 25 nucleotides.

#### Additional description of prior art

Oligonucleotides having a thiol (SH) group pendant from the  
 5'-terminus are not, as a class, novel. B.A. Connolly and P.  
 Rider, Nucleic Acids Research 13, 4485-4502 (1985) prepared such  
 30 compounds by reacting S-trityl- $\omega$ -mercaptoalkanols with  
 O-methoxymorpholinophosphite to give S-trityl-O-methoxy-  
 morpholinophosphites of formula




- 7 -

where Ph = phenyl and x = 2, 3 or 6, and then coupling these compounds with oligonucleotides which had been prepared by a solid phase phosphoramidite method, oxidising the resultant phosphite to phosphate, and de-protecting the thiol group.

05 Connolly and Rider used these compounds in reactions to label the thiol-terminated oligonucleotides with the fluorophore, N-iodoacetyl- N'-(5-sulpho-1-naphthyl)ethylenediamine (AEDANS) or N-(1-anilino-4-naphthyl)maleimide (ANM). In the reaction with AEDANS, the iodine atom is displaced, forming a -S-CH<sub>2</sub>-CO-

10 linkage, while in the reaction with ANM an electrophilic addition of the double bond produces a linkage:



15 In PCT Patent Specification WO 89/02931 (Cetus) published 6th April 1989, oligonucleotide "functionalizing reagents" are described. These have a pendant thiol, amino or hydroxyl group linked to the 5'- phosphate group by a spacer chain of formula -(CH<sub>2</sub>)<sub>2</sub>-(OCH<sub>2</sub>CH<sub>2</sub>)<sub>n</sub>-CH<sub>2</sub>CHR\*-O- where the oxygen atom shown is that

20 of the phosphate group and R\* represents H, CH<sub>2</sub>OH or tritylated CH<sub>2</sub>OH. These reagents are used for reaction with a horseradish peroxidase (HRP) derivative in order to label the oligonucleotide with an enzyme. The HRP derivative has a maleimide termination, producing the same kind of linkage as described in the Connolly

25 and Rider paper.

Thiol linkages have been used to attach proteins to supports. See, for example, "Solid Phase Biochemistry" ed. W.H. Scanten, John Wiley & Sons 1983, Chapter 7 "Immobilized Enzymes" by John F. Kennedy and J.M.S. Cabral, pages 301 and 302

30 "Affinity Chromatography - principles and methods", published by Pharmacia AB, 1986-1988, pages 35-45.

- 8 -

Brief description of the drawings

Figs. 1 and 2 are graphs in which the amount of hybridisation achieved by immobilised polynucleotides of the invention, assayed by heat-denaturing labelled hybrids, is represented by plots of amounts of labelled material released from the hybrids into solution against temperature of denaturation and compared with various controls;


Figures 3 and 4 are similar graphs but referring to immobilised polynucleotides of the prior art; and

Figure 5 is a similar graph showing the effect of the inclusion of a spacer arm in the immobilised polynucleotides of the invention.

Description of the preferred embodiments

While the preferred use of the invention, as currently contemplated, is in the PCR reaction, the invention can be used in the context of any procedure of immobilising or insolubilising a polynucleotide, especially a heterogenous assay procedure. Thus, the invention is applicable in such assay procedures described in the above-mentioned Matthews and Kricka review paper.

The support material is not critical and can be any of those conventionally used. One convenient material is beads which already have thiol groups attached. These are available commercially for the purposes of affinity chromatography of proteins. See, for example, the above-cited "Affinity Chromatography - principles and methods", published by Pharmacia AB, which describes S-protected thiolated "Sephacrose" beads of formula:

Sephacrose residue  $-O-CH_2-CH(OH)-CH_2-S-S-$   (the 2-pyridyl group being protective).

Various glasses can be used as supports when activated to provide suitable functional groups. Thus controlled pore glass (CPG) or any other glass of high surface area can be used.

Virtually any conventional chemical linkages can be used in building up a chain between the support to the -SH termination, even the CNBr or carbodiimide method, so long as they do not

- 9 -

provide the final attachment to the polynucleotide. Obviously, for use in the PCR, thermally susceptible linkages are to be avoided.

05 While the elements of the linkage can be provided in any order, it will be appreciated that it is desirable not to cause any reaction which might be non-specific. It will almost always be desirable to form the -S-S- bond last when preparing the immobilised polynucleotides. By way of example a conventional aminoalkylating agent can be reacted with a support such as CPG  
10 to provide amino terminations. The amino-functional support can then be reacted with cysteine in a peptide coupling reaction to provide the SH termination required. However, preliminary indications suggest that such a cysteine link might not produce the desired high specificity of binding of the support to the DNA  
15 to be immobilised and at present a mercaptoalkyl termination is preferred. Thus, a support, such as CPG is preferably silanised by an ( $\omega$ -mercaptoalkyl) trimethoxysilane, conveniently (3-mercaptopropyl) trimethoxysilane. This silanised support is then reacted with the thiol- terminated polynucleotide.

20 The linkage between the polynucleotide and the support will normally include a spacer arm between the polynucleotide and the -S-S- linkage, the -S-S- linkage and the support, or both. Alternatively or additionally the polynucleotide can itself contain a spacer arm, of one or more nucleotides, usually 3 to 20  
25 and preferably 4 to 15, between its 5'-end and the nearest "relevant" nucleotide. Where the polynucleotide is a sequence complementary to another sequence to which it is to be hybridised, the "relevant" nucleotide will be the last nucleotide of that complementary sequence, (the "c-target" sequence). This  
30 nucleotide spacer arm consists of "irrelevant" polynucleotides which do not interfere with or participate in hybridisation. For the purposes of reckoning its length, the nearest "relevant" nucleotide is not counted in, but the 5'-end nucleotide is counted in. The total length of spacer arm (whether in the  
35 linkage or the polynucleotide or both) will depend on the nature

- 10 -

of the linkage and its spatial configuration. In general, a straight chain of from 5 to 27 atoms and nucleotides between the support and the relevant 5'-end nucleotide (inclusive of the two S atoms) is suggested. Too short a chain would tend to bring the support too close to the polynucleotide chain for successful hybridisation to occur, while if the linkage is too lengthy the support might dangle at such a distance as to wrap itself over the relevant 5' end nucleotide and its neighbours. This would probably interfere with successful use of a supported oligonucleotide as a primer in the PCR.

Preferably the total spacer arms conform to the general formula  $(N)_x-(L_1)_y-S-S-(L_2)_z$  e.g. in the manner illustrated below, using arbitrary, imaginary sequences:

```

--NNNGCTTAGCTNNNNNNNNNN 3'
   CGAATCGA                5'

```

$(N)_x-(L_1)_y-S-S-(L_2)_z$ -Support

where the top sequence is that of the target (analyte) polynucleotide, the bottom sequence is that of an oligo primer immobilised according to the invention; N represents a nucleotide in the spacer arm upstream of the end of the "c-target" sequence;

$L_1$  and  $L_2$  represent atoms in a covalent chain from the end nucleotide to the support, on each side of the two sulphur atoms of the -S-S-linkage;

x, y and z are 0 or integers and the sum of x, y and z is 3 to 25, preferably 4 to 25, especially 6 to 20.

It will be appreciated that the invention is usable merely for isolating a polynucleotide without necessarily hybridising or annealing it. In such circumstances a spacer arm will frequently offer no advantage.

The PCR is described in the above-cited references, the disclosures of which are herein incorporated by reference. Any nucleic sequence can be specifically amplified by the PCR. It is only necessary that a sufficient number of bases at each end be

- 11 -

sequenced so that two oligonucleotide ("oligo") primers can be prepared, complementary to sequences at or near the ends of each strand or, at least, sufficiently well separated that the sequence of interest lies between the 3'-ends of the two  
05 primers. One oligo primer is called the forward primer, because it primes 5' to 3' synthesis of complement to the coding strand of the polynucleotide. The other is the reverse primer which primes 5' to 3' synthesis of complement to the non-coding strand. If neither strand codes, the designations are arbitrary.

10 The PCR normally comprises broadly three steps per cycle:  
(1) annealing forward and reverse oligonucleotide primers to the strands of a polynucleotide to be amplified, these strands having been first separated, annealing being carried out typically at a temperature of 30 to 60°C;  
15 (2) extending the primed sequences along their respective template strands of the polynucleotide to be amplified, at a temperature typically of 60 to 80°C.  
(3) separating the synthesised strands from their templates at a temperature effective for this purpose, typically from 80 to  
20 100°C, especially at about 90°C.

The cycle is then repeated, using the products of each separation step (3) as the templates for the ensuing annealing step (1) of the next cycle. Products are conveniently detected by labelling the nucleotides used for the chain extension and  
25 determining the label attached to the products. Labelling can be done radioactively e.g. with <sup>32</sup>P or by biotinylation, for example, and the labelled products immobilised and separated from the reaction medium. In another mode, the PCR can be carried out in solution and the products detected by carrying the PCR to the  
30 end of a separation step (3), and probing the strands with a probe which is attached to a support or to which a support is later attached. The amount of label attached to the support is then determined.

Of course, it is not critical to label the nucleotides  
35 incorporated in the PCR. Instead the PCR products can be

- 12 -

subjected to a sandwich assay in which a two-site probe is used, site A being capable of binding specifically to the PCR product which it is hoped to detect and site B being capable of hybridising with an immobilised polynucleotide of the invention.

05 Another method of detecting PCR products on a solid support depends on measuring the thickness of the layer deposited on the solid phase. This can be done by measuring changes of optical path through the layered film: see literature of Medical Products Inc., Boulder, Colorado, USA.

10 It is also possible to use the 5' thiol-derivatised primers (carrying a free or protected -SH group) in solution in the PCR and subsequently linking the amplified labelled (or unlabelled) products to the thiol-derivatised solid support by means of the invention. The attached PCR products may be detected by any  
15 number of methods including those cited above.

Products attached to the solid phase through the linkage of the invention can be released therefrom by any of the known methods of breaking -S-S- bonds, such as by prolonged action of a high concentration of dithiothreitol or 2-mercaptoethanol. Note,  
20 however, that the relatively low concentrations of these reagents often present in conventional PCR buffer systems will not normally break the S-S bonds.

Any number of polynucleotides can be linked to the same integral unit (particle, sheet, bead, tube etc.) of the support  
25 material, provided that there is no interference between polynucleotides which would hinder their end use, e.g. in an assay.

The following Examples illustrate the invention.

#### EXAMPLE 1

30 Example 1 illustrates the hybridisation capacity of an oligonucleotide bonded to a support via an -S-S- linkage, in accordance with the invention. The oligonucleotide was used with and without a 4-nucleotide spacer between the c-target sequence and the 5'-end.

35 All operations were carried out at room temperature (about 20°C) except as otherwise described.

- 13 -

## THE OLIGONUCLEOTIDES AND PROBES USED

The oligonucleotide synthesised for coupling to the beads is that of the forward primer complementary to a sequence of the human papilloma virus type 16 successfully applied in the PCR for amplification of a 120 base-pair fragment of HPV16 DNA:

05 5' TCAAAGCCACTGTGTCCTG 3' (20mer) D99 (in-house designation) identified as Sequence ID No. 1.

(1) To prepare a thiol-terminated oligo, a 5'-spacer was added, composed of an additional 4 dTTP residues, the last 5' terminal dTTP being a fully protected thiol phosphoamidite.

10 (2) For comparative purposes, the same oligo as in (1) above was prepared, except that an "aminolink II" was incorporated on the terminal 5' dTTP (4 dTTP spacer included). "Aminolink II" is a reagent sold by Applied Biosystems Inc. for derivatisation of the 5'- terminus of a synthetic oligonucleotide. It is a methyl phosphoramidite of formula  $\text{CF}_3\text{CO NH}(\text{CH}_2)_6\text{OP}(\text{OCH}_3)\text{N}[\text{CH}(\text{CH}_3)_2]_2$  and is used in the beta-cyanoethyl phosphoamidite synthesis to introduce an aminohexyl termination (the terminal  $\text{CF}_3\text{CO-}$  group being cleaved off at the end of the synthesis).

20 (3) The hybridisation probes prepared were either a sequence complementary to D99 i.e:

3' AGTTTCGGTGACACAGGAC 5' (anti-D99) identified as Sequence ID No. 2.

or, as a control, the reverse primer sequence oligo for HPV16 i.e:  
25 3' ACGTCTAGTAGTTCTTGTGC 5' (non-complementary to D99 oligo) identified as Sequence ID No. 3.

## SYNTHESIS OF OLIGONUCLEOTIDES

The oligos were synthesised on a Biotec Instruments BT8500 automatic machine, using the well established cyanoethyl phosphoamidite coupling chemistry. The last base to be added at the 5' end of the oligo was a fully dimethoxytrityl protected, thiol phosphoamidite, introduced via line Q on the BT8500. The oligo was cleaved from the controlled pore glass solid phase in the normal way with aqueous ammonia, using a 'trityl ON' cleavage method. The free oligo was then dried at 50°C under vacuum. It is stable for long periods at -20°C.

- 14 -

## COUPLING OF THIOL-TERMINATED OLIGONUCLEOTIDE TO BEADS VIA DITHIO LINKAGES.

## (i) activation of thiol oligo:

0.04  $\mu$ mole of the oligo, (10 OD<sub>260</sub> units) was dissolved in  
100  $\mu$ l of 0.1M triethanolamine acetate (TEAA) buffer pH 7.5. 15 $\mu$ l  
of 1M silver nitrate solution was added, vortexed, and incubated  
at room temperature for 30 mins. This cleaved the  
dimethoxytrityl protective group off the thiol, with approx. 70%  
efficiency. 20 $\mu$ l of 1.0M dithiothreitol (DTT) was added,  
vortexed and reacted for 5 mins. The reaction mixture was  
centrifuged at 3000 rpm for 5 mins and the supernatant removed.  
100 $\mu$ l of TEAA buffer was added to the precipitate, which was  
vortexed, centrifuged and the supernatants combined. This oligo  
solution was stable for months at -20°C.

## (ii) Activation of beads and coupling:

Either 0.04 or 0.4  $\mu$ mole of "Biomag" 4135 thiol-terminated  
magnetic affinity chromatography support beads, a product of  
Advanced Magnetix Inc., Cambridge, Mass. USA, available in the  
UK from Metachem Diagnostics Ltd. of Northampton, (either 1mg,  
60 $\mu$ l or 10 mg, 0.6 ml.) were washed 3 times with 0.05M TEAA  
buffer to remove all mercaptoethanol. The above-prepared oligo  
solution (200 $\mu$ l) was added, and vortexed. The solution was  
extracted 3 times with ethyl acetate and twice with diethyl ether  
to remove all DTT and nitrogen was blown over solution to remove  
all the solvent. 40  $\mu$ l of iodine solution (100mg per ml in  
glacial acetic acid) was added. The supernatant (minus beads)  
should be brown at this stage; if not, iodine solution should be  
added in 20 $\mu$ l aliquots until it turns brown. The solution and  
beads were then vortexed and reacted for 30 min. to couple the  
beads to the oligo. After coupling, the beads were centrifuged  
and washed three times with 0.05M TEAA buffer to remove iodine  
and were then ready for use. To date, 70% of the activated oligo  
has been shown to bind to the beads, i.e. a total of 0.02  $\mu$ moles  
per 1mg or 10 mg of beads. Since the protective group is cleaved  
with 70% yield and 70% of the activated oligo binds to the beads,

- 15 -

the yield is 70% = 49% with respect to the original oligo.

#### COUPLING OF AMINE-TERMINATED OLIGONUCLEOTIDE TO BEADS

(a) via cyanogen bromide.

05 The amino-terminated D99 (4dTTP spaced) oligo (2) prepared above was coupled to Dynabead M450 beads (Dynal UK Ltd) having -OH active groups according to the method described by V. Lund et. al., loc. cit. (0.04  $\mu$  mole DNA to 10 mg of beads).

10 Beads were activated by incubation for 30 mins. in distilled water, followed by raising the pH to 11.5 with 2M sodium hydroxide and incubation for 50 mins. 30mg of cyanogen bromide was added and the pH re-adjusted to 11.5 with 2M sodium hydroxide. The beads were incubated on a roller for 10 mins followed by 5 washes with distilled water and resuspended in 10mM sodium bicarbonate buffer, pH 8.4

15 0.08  $\mu$ mole of oligo was added to 1ml of 1-methyl imidazole buffer pH 7 (Sigma) containing 0.1M 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide (Sigma), 0.25M ethylenediamine (Sigma) and incubated at 50°C for 3 hrs. 60  $\mu$ l of 3M sodium acetate, pH6.5 were added and 1 ml ice cold ethanol, mixed and incubated  
20 at -80°C for 2 hrs. The precipitate (comprising the amine-activated oligo), after centrifugation, was dried in a vacuum dessicator and reconstituted in 600  $\mu$ l 10 mM sodium bicarbonate buffer, pH8.0.

25 The above 600  $\mu$ l (0.08  $\mu$ mole) of activated oligo was mixed with 10 mg amine activated beads and incubated for more than 24 hrs on a roller. Control couplings were also performed using unactivated beads incubated with activated oligo or activated beads with unactivated oligo.

(b) via carbodiimide

30 Oligo was coupled to M450 beads via carbodiimide according to the above Lund et al. reference. Thus, 0.08  $\mu$ mole of activated oligo was added to 10 mg beads in the presence 0.04M sodium 2-(N-morpholino)ethane sulfonate containing 25 mg 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide and incubated overnight at 45°C.  
35 Control couplings were performed in the absence of the

- 16 -

carbodiimide reagent.

#### PREPARATION OF PROBES

Anti-D99 oligo was 3' end labelled with  $^{32}\text{P}$ -dideoxyATP using a kit supplied by Amersham International plc and separated on a  
05 G-50 "Sephadose" column. Labelled anti-D99 was added to unlabelled anti-D99 to give a 4-5% label concentration.

#### HYBRIDISATION OF THE IMMOBILISED OLIGONUCLEOTIDES TO LABELLED PROBES

Beads with or without oligo (0.02  $\mu\text{mole}$  per mg. or 10mg)  
10 attached by the methods described above were incubated with a molar excess (0.03  $\mu\text{mole}$ ) of anti-D99 (per mg. or 10 mg of beads) (4-5% 3'-end labelled with  $^{32}\text{P}$ ) in 2 x saline sodium citrate (SSC) buffer at 40°C for 2.5 hrs (1ml total volume). The supernatants were removed and discarded and the beads washed 4  
15 times in 2 x SSC at 40°C, to remove thoroughly excess labelled probe.

#### MEASUREMENT OF AMOUNT OF HYBRIDISATION

The hybridisation capacity of the oligos attached to the beads was then measured by dissociating the labelled probe DNA  
20 strand from the bead-bonded oligo strand and measuring the amount of label released into solution. Thus, the beads were then sequentially incubated in 0.5ml of 2 x SSC for 5 mins at 10°C temperature increments up to 90°C, supernatants were removed at the end of each cycle and the number of radioactivity counts per  
25 minute (cpm) assessed by Cerenkov-counting. A final further incubation of 90°C in the presence of 2% mercaptoethanol in 2 x SSC was performed and the cpm in the supernatant and remaining on the beads determined.

The results are shown graphically in Figures 1-4 of the  
30 drawings in which temperature is plotted on the abscissa and radioactivity released into solution in cpm on the ordinate. At the right-hand side, on a separate abscissa and ordinate the radioactivity remaining on the beads after the final 90°C wash is shown.

35 Figure 1 relates to 10 mg beads dithio-coupled to 0.2  $\mu\text{mole}$

- 17 -

of oligo D99. The filled squares show the cpm values obtained using the dithio-coupled beads hybridised to labelled complementary oligonucleotide, while the open triangles show the cpm values for the same beads incubated under the hybridisation conditions with the control non-complementary oligonucleotide. The open circles depict the amount of label in the supernatant using unactivated thiol beads (i.e. in the absence of D99) incubated under hybridisation conditions with the complementary (anti-D99) or non-complementary probes (the results were the same whichever probes were used). The right hand side shows the cpm remaining on the beads after the 90°C wash in the presence. 2-mercaptoethanol breaks the -S-S- bond, so these results are a measure of non-specific binding. Similar results (not shown) were obtained in the absence of mercaptoethanol (mean of two experiments).

It will be seen that a satisfactory curve was obtained with the hybrids formed from the dithio-linked beads of the invention. As expected, dissociation of the hybrid strands increased with elevated temperature. The curve is indicative of strong hybridisation.

Figure 2 shows the results obtained from the same experiments performed using 10 mg of beads with or without 0.2  $\mu$ mole of oligo D99 coupled via the dithio linkage. Filled squares show cpm in supernatants from dithio-linked D99 beads hybridised to labelled complementary (anti-D99), probe whilst open circles represent values obtained using unactivated beads with labelled anti-D99. The results for unactivated beads incubated with non-complementary oligo, and dithio-linked D99 beads incubated with non-complementary oligo are omitted for clarity because they were almost identical to the open circle results, with one exception. The exception was that the dithio-linked D99/non-complementary oligo gave a radioactivity count on the beads between that for dithio-linked D99/non-complementary oligo (filled square) and the unactivated/complementary oligo (open circle).

- 18 -

The results for the dithio-linked beads of the invention were more erratic than in Figure 1, doubtless due to the low ratio of oligo to beads in the coupling reaction.

#### STABILITY OF LINKAGE

05 It has also been determined that the dithio-linked D99 oligo, either without any nucleotide spacing or with the 4dT spacing as above (0.2µm per 10mg of the above-described beads) withstands pre-incubation for 5 to 30 minutes at temperatures of 60 to 90°C before hybridisation. After carrying out hybridisation and  
10 measurement of the amount of hybridisation, as described above, the number of radioactivity counts obtained was satisfactorily high, the maximum being about the same order as that of Figure 1.

#### COMPARATIVE EXPERIMENTS

Figure 3 shows the results of identical experiments obtained  
15 with 10 mg beads coupled to 0.08 micromole of D99 via the cyanogen bromide linkage. Filled circles show cpm in supernatants after hybridisation with an excess of tracer anti-D99 whilst the open symbols show the values obtained using unactivated beads hybridised to labelled anti-D99 or incubated  
20 with non-complementary oligo, or coupled beads incubated with labelled non-complementary oligo.

The results in Figures 3 and 4 ought to be multiplied by 2.5 in order to be comparable with Figure 1 (because of the different ratio of beads to oligo in the coupling reaction). However, this  
25 would not significantly affect the comparison because the degree of hybridisation of the dithio-linked oligos of the invention is of the order of 100-fold greater ( $10^5$  cpm versus  $10^3$  cpm).

Figure 4 shows the results obtained as in Figure 3 using beads linked to D99 via carbodiimide chemistry.

#### 30 EXAMPLE 2 (Comparative)

Experiments performed likewise with control pore glass coupling as described for the glass capillary of D99 via cyanogen bromide and carbodiimide show almost identical results to those of Example 1 using those coupling reagents, i.e. as reported in  
35 Figures 3 and 4.

- 19 -

EXAMPLE 3

This Example illustrates the effect on hybridisation of including an 8dT spacer arm in the immobilised oligo. Proceeding as in Example 1, with 0.2  $\mu$ mole of oligo D99 dithio-linked to 10 mg of the magnetic beads (a) with an 8dT spacer arm or (b) for comparison, without a nucleotide spacer arm, the results shown in Figure 5 were obtained. The filled circles represent results from the 8dT spaced immobilised D99, while the filled squares are those for the unspaced immobilised D99. Beads which were not coupled to the D99 gave counts of virtually zero. It is seen that the counts were somewhat higher from the nucleotide spacer arm-linked beads, indicating improved hybridisation.

EXAMPLE 4

This Example illustrates the effect on the hybridisation of including a long (15 dT) spacer arm in the immobilised oligo.

Following the procedure of Example 1, using 10 mg of the beads and, in one run, pre-washing the oligo-coupled beads for 5 minutes at 80°C instead of at room temperature, and using a thiol-terminated oligo with a 15 dT instead of a 4 dT spacer, the data shown in the Table below were generated. There is a reduction in the amount of specific hybridisation compared with Example 1 in which the spacer was shorter. Possibly such a long spacer creates steric hindrance to hybridising anti-D99.

TABLE

Results of hybridisation of labelled anti-D99 to 0.2  $\mu$ M 15 dT D99 oligo linked to 10 mg magnetic beads. Values represent counts released into supernatant following incubation in 2xSSC buffer at different temperatures shown in the left-hand column; at the bottom the counts from the beads are shown, i.e. analogously to the right-hand side of the Figures.

- 20 -

Wash Temp °C	Control (unactivated Beads)	15dT D99 (room temp pre-wash)	15dT D99 (80°C pre-wash)
40	103853	139028	183856
40	4100	11549	15336
40	1015	3769	1994
40	673	3982	1285
50	1371	7524	5018
60	2452	11495	9587
70	2056	24070	119099
80	4986	21539	10991
90	6152	29617	13471
90 + 2ME	4806	14904	11696
Beads	12499	73681	52337

2ME = 2-mercaptoethanol

EXAMPLE 5

This Example illustrates immobilisation of DNA to a non-thiolated support (control pore glass) by constructing a dithio linkage.

- 05 0.25 g of 3000 Angstrom CPG, mesh size 60-120 Angstrom were reacted with 0.15ml (3-mercaptopropyl) trimethoxysilane (Aldrich Chemical Co: technical grade 75%) in 3ml of acetone for 5 minutes at room temperature. The CPG was then washed 3 times with acetone, 3 times with diethyl ether and air dried. The yield in
- 10 this experiment was 8 nanomoles/mg of available thiol groups, as assessed coupling cysteine to the mercaptopropyl-terminated CPG, cleaving the S-S bond, oxidising the cysteine and then amino acid analysis. Taking account of the reduced surface area of CPG compared with the magnetic beads, the yield is some 25-fold less
- 15 than the thiol groups coupled in previous experiments. Thiol-terminated D99 oligos with 4dT spacer (0.4  $\mu$ mole) were then added to the CPG (1 mg.) in the way described in Example 1.

- The D99 oligos coupled to the activated CPG were then hybridised to labelled anti-D99, as in previous Examples. For
- 20 comparison, the same hybridisation was performed on 0.2 $\mu$ mole of

- 21 -

D99 coupled to 1mg of magnetic beads as in Example 1.

Since the CPG has 20 fold less thiol groups present on the surface, the hybridisation capacity of this DNA is considered as good as (if not a little better) than that of the magnetic beads.


#### Counts in Supernatants

Wash Temp °C	Control (Unactivated)	Controlled Pore Glass Activated No D99 present	Glass Activated coupled to D99	Magnetic Beads Activated No D99 present	Magnetic Beads Activated coupled to D99
40	58256	80682	77450	(61051)	50056
40	4338	3878	4825	(3410)	3438
40	568	377	1084	(1433)	1588
40	160	150	645	(952)	1633
50	124	159	1421	(1669)	2419
60	225	238	5041	(3324)	10701
70	220	314	6205	(4877)	49296
80	394	384	5974	(7747)	102702
90	314	347	705	(4819)	21284
Beads	1134	1250	1358	17074	11282

#### 05 EXAMPLE 6

This following Example demonstrates that double-stranded DNA simulating a PCR product, immobilised onto magnetic particles (Biomag) via the dithio-linkage described in Example 1, can be labelled by a 3' end-labelling reaction.

- 10     3 mg magnetic beads having oligo D99 with a 4 dT spacer (0.2  $\mu$ M per 10mg beads) coupled via the dithio-linkage of the invention were incubated for 1 hour at 40°C with an excess of complementary oligo (anti-D99) either (1) as such or (2) with an additional 5'-poly dG sequence (of 6 dG bases) extending past the
- 15     free 3' terminus of the immobilised oligo D99, (as shown below):



The magnetic beads carrying this duplex of immobilised

- 22 -

double-stranded DNA were used as template in the 3' end-labelling reaction employing  $^{32}\text{P}$ -dCTP as the labelling nucleotide, and Tag polymerase or Klenow fragment as the enzymes in Tag polymerase buffer. After labelling, whereby cytidine (dC) bases are added to complement the guanosine (dG) tail, the reaction mixture was heated to 90°C, and whilst still at this temperature, the beads were removed by centrifugation. The beads were washed with 2xSSC at 90°C and the radioactivity (cpm) remaining on them was then determined by Cerenkov-counting. The results (Table 1) were compared to those obtained using D99-beads without enzyme present, or using magnetic beads alone (i.e. no immobilised D99).

The results demonstrate that substantial radioactive label (and therefore incorporation of  $^{32}\text{P}$ -dCTP to the 3' terminus of oligo D99) is present only using magnetic beads with dithio-linked oligo D99 in the presence of either Tag polymerase or Klenow fragment. Thus, the 3' terminus of the dithio-linked oligo D99 on the magnetic beads is accessible to the DNA polymerase activity of both enzymes under the appropriate conditions. When Klenow fragment was used as the enzyme for the labelling reaction, the beads having the D99/anti-D99 duplex without the dG tail showed a high "background" radioactive count. This can be ascribed to intrinsic exonuclease activity of Klenow fragment.

TABLE 1

Amount of radioactivity (cpm) on beads after being subjected to 3' end-labelling reaction using  $^{32}\text{P}$ -dCTP

Enzyme	D99 Beads + anti-D99+6G	D99 Beads + anti-D99 (control)	Plain Beads (no D99)
None	627	2004	774
Klenow	388359	94225	11093
<u>Tag</u> polymerase	1137481	8598	921

- 23 -

EXAMPLE 7

This Example demonstrates that DNA (oligo D99) dithio-linked to magnetic beads can function as the forward primer in the polymerase chain reaction for the amplification of target DNA (the E6 region of human papilloma virus type 16 (HPV16) genomic DNA), resulting in immobilisation of the PCR products as double stranded or (by heating the product to 90°C immediately before separating solid from liquid phases) single stranded DNA.

3 mg magnetic beads coupled to oligo D99 (as in the previous example) were added to a total 100 µl PCR reaction mixture composed of recommended PCR buffer (Perkin-Elmer Cetus) in the presence of Caski DNA (a cell line infected with HPV16 genomic DNA) free (i.e. not immobilised) reverse primer (referred to as non-complementary primer in Example 1) or both free non-complementary primer and oligo D99. Reactants were preheated to 98°C for 7 minutes 5 units of Taq polymerase were added and a PCR was carried out for 40 temperature cycles composed of 96°C for 30 seconds (denaturation), 40°C for 30 seconds (annealing of primer to target) and 72°C for 1 minute (DNA synthesis by primer extension) performed on a Wolfson Programmable Thermal Cycler. Following cycling, supernatants were removed and the beads resuspended in 2xSSC heated to 90°C. The magnetic beads were removed by centrifugation and washed once with 2xSSC buffer at room temperature. This results in the dithio-linked oligo D99 and its extension product remaining on the magnetic beads as single-stranded DNA. The beads were then probed with a 32p hexanucleotide-labelled 38mer oligo complementary to a mid-sequence of the expected HPV16 PCR product (probe sequence = 5' AAAGATTCCATAATATAAGGGGCGGTGACCGGTCGATG 3', identified as Sequence ID No. 4). Hybridisation of probe and assessment of hybridised probe were performed as described in Example 1, except that the amount of radioactivity remaining on the beads was determined. The results are given in Table 2 which also includes the data obtained using magnetic beads alone (i.e. no dithio-linked oligo D99) in the presence or absence of Taq polymerase and in reaction mixtures containing

- 24 -

free (i.e. unlinked) reverse primer and forward primer.

TABLE 2

Results of hybridising  $^{32}\text{P}$ -labelled mid-sequence probe to oligo D99 coupled magnetic beads after PCR cycling. Numbers refer to cpm after washes at different temperatures.

Bead Type	Free Oligo	<u>Tag</u>	40°C	50°C	60°C	70°C	80°C	90°C
no D99	F + R	+	13748	4948	5057	5080	7487	3783
+ D99	R alone	+	80287	77817	54634	19681	13724	9993
+ D99	F + R	+	66574	67716	61856	38463	34809	19369
no D99	F + R	-	4123	3129	2873	3770	4399	3084
+ D99	R alone	-	23069	23908	18456	16807	17337	11923
+ D99	F + R	-	22437	20035	18977	15365	13694	12813

F refers to forward oligo primer (i.e. D99) and R refers to reverse primer. "Tag" = Tag polymerase.

The results demonstrate that using dithio-linked D99 magnetic particles, in the presence of free reverse primer (or both primers free) and Tag polymerase, specific amplification of the HPV16 E6 region is permissible.

The reaction scheme below shows a simplified version of a PCR carried out in the manner of Example 7, with a forward primer (D99) immobilised, a reverse primer in solution, and a single molecule of double-stranded HPV16 DNA.

If one amplification cycle is performed on dsDNA of HPV16 consisting of strands labelled "B" and "C" the results would be:

(1) Extension of the immobilised forward primer to yield one new HPV16 strand of DNA immobilised to the solid phase, labelled "A".

(2) Extension of the reverse primer in solution to yield one new strand of HPV16 DNA which is opposite in sequence and orientation (i.e. complementary) to the strand generated in (1) above. This new strand is labelled "D".

(3) The two separate strands "B" and "C", of the original HPV16 DNA.

- 25 -

Upon cooling the reaction mixture to allow re-annealing of each of the separate strands "A", "B", "C" and "D", the following immobilised products would be obtained:

05 (4) immobilised dsDNA composed of the new strand "A" formed by forward primer annealed to complementary strand "B" of HPV16 starting DNA template; or


(5) immobilised dsDNA composed of the new strand "A" formed by the forward primer annealed to the new complementary strand "D" generated by the reverse primer.

10 Both situations essentially result in one dsDNA immobilised and one in free solution. Further amplification in the presence of more of each primer, then (as in a regular PCR reaction) results in more dsDNA product (original template cannot increase) which is immobilised to the solid phase. By heating to 90-100°C,  
15 the dsDNA is made single stranded which, using the above conditions, results in all the forward primer product being immobilised and all the reverse primer product being in solution.



- 26 -

FIRST CYCLE


## STAGE 1 : ANNEALING OF PRIMERS



## STAGE 2 : PRIMER EXTENSION, FOLLOWED BY SEPARATING THE STRANDS

RE-ANNEALING OF THE SINGLE STRAND PRODUCTS

OR



Of course, if the reverse primer were also to be immobilised, then all the solid phase products would contain either the target HPV16 DNA (one strand or the other) or a copy of part of the target DNA made by the primer extension.

- 27 -

SEQUENCE LISTING

This sequence listing is provided in this International Patent Application to meet the requirements or wishes of certain contracting States (EPC countries, US, JP). The "General Information Section" is applicable only to US.

(1) GENERAL INFORMATION:

(i) Applicant : DAY, Philip J.R.  
FOX, John E.  
WALKER, Matthew R.

(ii) Title of Invention : Immobilised Polynucleotides

(iii) Number of Sequences : 4

(iv) Correspondence Address : Nixon & Vanderhye P.C.,  
14th Floor,  
2200 Clarendon Boulevard,  
Arlington,  
Virginia,  
U.S.A. 22201

(v) Computer Readable Form:

(a) Medium Type : Diskette, 5.25 inch, 360 Kb storage.  
(b) Computer : IBM PC/AT compatible.  
(c) Operating System: MS-DOS 3.2.  
(d) Software : Word Perfect ASCII File Format.

(vi) Current Application Data:

(a) Application Number :  
(b) Filing Date:  
(c) Classification:

(vii) Prior Application Data:

(a) Application Number : PCT/GB 90/  
(b) Filing Date :

(a) Application Number : GB 8915607.9  
(b) Filing Date : 07 JUL 1989

(a) Application Number : GB 8921327.6  
(b) Filing Date : 21 SEP 1989

(a) Application Number : GB 9008274.4  
(b) Filing Date : 11 APR 1990

(viii) Attorney/Agent Information:

(a) Name : Leonard C. Mitchard  
(b) Registration Number: 29,009  
(c) Reference/Docket Number :

- 28 -

## (ix) Telecommunication Data:

(a) Telephone : (703) 875-0400  
(b) Telefax : (703) 525-3468

(2) INFORMATION FOR SEQUENCE ID NO. 1

## (i) Sequence Characteristics :

(a) Length : 20 base pairs  
(b) Type : Nucleic acid  
(c) Strandedness : Double  
(d) Topology : Linear

(xi) Sequence Description : Sequence ID No. 1

TCAAAAGCCA CTGTGTCCTG 20

(2) INFORMATION FOR SEQUENCE ID NO. 2

## (i) Sequence Characteristics:

(a) Length : 20 bases  
(b) Type : Nucleic acid  
(c) Strandedness : Single  
(d) Topology : Linear

(xi) Sequence Description : Sequence ID No. 2

CAGGACACAC TGGCTTTTGA 20

(2) INFORMATION FOR SEQUENCE ID NO. 3

## (i) Sequence Characteristics:

(a) Length : 20 bases  
(b) Type : Nucleic acid  
(c) Strandedness : Single  
(d) Topology : Linear

(xi) Sequence Description : Sequence ID No. 3

CGTGTTCTTG ATGATCTGCA 20

(2) INFORMATION FOR SEQUENCE ID NO. 4

## (i) Sequence Characteristics

(a) Length : 38 bases  
(b) Type : Nucleic acid  
(c) Strandedness : Single  
(d) Topology : Linear


(xi) Sequence Description : Sequence ID No. 4

AAAGATTCCA TAATATAAGG GGCGGTGACC GGTCGATG 38

- 29 -

CLAIMS

1. An immobilised polynucleotide material comprising a support bound to a 5'-end of at least one polynucleotide through a linkage which comprises a dithio (-S-S-) group.
2. An immobilised polynucleotide material according to Claim 1  
05 wherein the polynucleotide contains a "c-target" base sequence complementary to a base sequence of interest in a target polynucleotide, and wherein the "c-target" sequence is spaced from the support so as to permit the c-target sequence to hybridise to the target polynucleotide.
3. An immobilised polynucleotide material according to Claim 2  
10 wherein the c-target sequence is spaced from the 5'-end of the polynucleotide by a spacer arm of one or more nucleotides which do not participate in or interfere with c-target/target hybridisation.
4. An immobilised polynucleotide material according to Claim 3  
15 wherein the nucleotide spacer arm is from 3 to 20 nucleotides long.
5. An immobilised polynucleotide material according to Claim 4  
20 wherein the nucleotide spacer arm is from 4 to 15 nucleotides long.
6. An immobilised polynucleotide material according to any preceding claim wherein the linkage includes a spacer arm between the support and the -S-S- group, between the -S-S- group and the 5'-end of the polynucleotide or both.
7. An immobilised polynucleotide according to Claim 2 comprising  
25 a nucleotide spacer arm according to Claim 3, 4 or 5 and a linkage spacer arm according to Claim 6, which together conform to the general formula:



30 where:

N is a nucleotide attached to the 5'-end of the c-target sequence and where there is more than one such nucleotide they may be the same or different;

- 30 -

$L_1$  and  $L_2$  are atoms in a chain from the 5'-end nucleotide of the polynucleotide to the support, on each side of the two S atoms of the -S-S-linkage;

05 x, y and z are 0 or integers and the sum of x, y and z is 3 to 25.

8. A method of producing an immobilised polynucleotide material according to Claim 1, which comprises reacting a 5'-(thiol-terminated) derivative of at least one polynucleotide with a support having a thiol group thereon, either or both of  
10 said thiol groups being -SH groups as such or derivatised as co-reactive -S-S- linkage-producing derivatives, to form a said -S-S- linkage between said thiol groups.

9. A method according to Claim 8, wherein the polynucleotide contains a "c-target" base sequence complementary to a target  
15 sequence of interest in another polynucleotide and wherein spacing is provided within the thiol-terminated polynucleotide between the target sequence and the thiol termination, within the thiolated support between the support and the thiol group or within both, said spacing being in total, after reaction to form  
20 the -S-S- linkage, effective to space the support from the c-target sequence to permit the c-target sequence to hybridise to the target sequence.

10. A method according to Claim 9 wherein spacing is provided as defined in Claim 4, 5 or 7.

25 11. A method of carrying out a polymerase chain reaction (PCR) in which an immobilised polynucleotide material claimed in any one of Claims 1 - 7 or prepared by a method claimed in any one of Claims 8 - 10 is substituted for either or both of the oligonucleotide primers used in the PCR and the amplified product  
30 of the PCR is separated on the solid phase.

12. A method of carrying out a PCR reaction which comprises:

(1) annealing forward and reverse oligonucleotide primers, which are immobilised polynucleotide materials as defined in Claim 11, to the strands of a polynucleotide to be amplified which serve as

- 31 -

templates, the annealing being carried out at a temperature of 30 to 60°C.

05 (2) extending the primed sequences along their respective template strands of the polynucleotide to be amplified, at a temperature of from 60 to 80°C,

(3) separating the thus synthesised strands from their templates at a temperature of 80 to 100°C and repeating the process by using the separated strands as templates.

10 13. A method according to Claim 11 or 12 wherein the amplified products of the PCR are labelled and the PCR is used to assay a sequence of the polynucleotide to be amplified.

15 14. A method of heterogeneous assay for an analyte nucleic acid, which comprises subjecting an immobilised polynucleotide material according to any one of Claims 1 - 7 or prepared by a method claimed in any one of Claims 8 - 10, having a "c-target" base sequence complementary to a target sequence of analyte nucleic acid present in a liquid phase analyte, hybridising the c-target sequence to the target sequence separating the phases and determining the occurrence or extent of hybridisation.

20 15. A method according to Claim 14 wherein the analyte nucleic acid is generated by a liquid phase PCR.

1/4




Fig.1

2/4




Fig.2

3/4




Fig.3




Fig.4

4/4




Fig.5

# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 90/01040

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>5</sup> : C 07 H 21/00, C 12 Q 1/68																	
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">IPC<sup>5</sup></td> <td style="padding: 5px;">C 07 H 21/00, C 12 Q 1/00</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	IPC <sup>5</sup>	C 07 H 21/00, C 12 Q 1/00											
Classification System	Classification Symbols																
IPC <sup>5</sup>	C 07 H 21/00, C 12 Q 1/00																
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category <sup>10</sup></th> <th style="width: 70%; border-bottom: 1px solid black;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 20%; border-bottom: 1px solid black;">Relevant to Claim No. <sup>13</sup></th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">WO, A, 88/01302 (SISKA DIAGNOSTICS INC.) 25 February 1988 see the whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,2,6,8,9</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">EP, A, 0192197 (MOLECULAR DIAGNOSTICS INC.) 27 August 1986 see the whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-3,6</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">Nucleic Acids Research, volume 15, no. 13, 10 July 1987, R. Zuckermann et al.: "Efficient methods for attachment of thiol specific probes to the 3'-ends of synthetic oligodeoxyribonucleotides", page 5316 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">EP, A, 0269445 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 1 June 1988 see the whole document, especially page 9, lines 13-23 -----</td> <td style="text-align: center; vertical-align: top; padding: 5px;">9</td> </tr> </table>			Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	WO, A, 88/01302 (SISKA DIAGNOSTICS INC.) 25 February 1988 see the whole document --	1,2,6,8,9	X	EP, A, 0192197 (MOLECULAR DIAGNOSTICS INC.) 27 August 1986 see the whole document --	1-3,6	A	Nucleic Acids Research, volume 15, no. 13, 10 July 1987, R. Zuckermann et al.: "Efficient methods for attachment of thiol specific probes to the 3'-ends of synthetic oligodeoxyribonucleotides", page 5316 --	1	A	EP, A, 0269445 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 1 June 1988 see the whole document, especially page 9, lines 13-23 -----	9
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>															
X	WO, A, 88/01302 (SISKA DIAGNOSTICS INC.) 25 February 1988 see the whole document --	1,2,6,8,9															
X	EP, A, 0192197 (MOLECULAR DIAGNOSTICS INC.) 27 August 1986 see the whole document --	1-3,6															
A	Nucleic Acids Research, volume 15, no. 13, 10 July 1987, R. Zuckermann et al.: "Efficient methods for attachment of thiol specific probes to the 3'-ends of synthetic oligodeoxyribonucleotides", page 5316 --	1															
A	EP, A, 0269445 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 1 June 1988 see the whole document, especially page 9, lines 13-23 -----	9															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>																	
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of the Actual Completion of the International Search             11th September 1990         </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of Mailing of this International Search Report             24. 10. 90         </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">           International Searching Authority             EUROPEAN PATENT OFFICE         </td> <td style="border-bottom: 1px solid black; padding: 5px;">           Signature of Authorized Officer              H. Ballesteros         </td> </tr> </table>			Date of the Actual Completion of the International Search  11th September 1990	Date of Mailing of this International Search Report  24. 10. 90	International Searching Authority  EUROPEAN PATENT OFFICE	Signature of Authorized Officer  H. Ballesteros											
Date of the Actual Completion of the International Search  11th September 1990	Date of Mailing of this International Search Report  24. 10. 90																
International Searching Authority  EUROPEAN PATENT OFFICE	Signature of Authorized Officer  H. Ballesteros																

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 9001040

SA 38156

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 10/10/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8801302	25-02-88	EP-A- 0276302 JP-T- 1500461	03-08-88 16-02-89
EP-A- 0192197	27-08-86	US-A- 4818681 JP-A- 61246201	04-04-89 01-11-86
EP-A- 0269445	01-06-88	JP-A- 63294800	01-12-88

**THIS PAGE BLANK (USPTO)**